p63 + CK5

Product Description

The p63 + CK5 Multiplex IHC stain has been especially designed for squamous cell carcinomas, particularly those derived in lung cancer. p63, a homolog of the tumor suppressor p53, has been identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate.¹⁵ CK5 is a 58 kDa protein that is closely related to CK6.16 CK5 tissue distribution is in many non-keratinizing stratified squamous epithelia such as tongue mucosa, basal epithelia hair follicles, trachea, as well as basal cells in prostate glands and myoepithelial cells in mammary glands.¹⁶

Specifications

Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.

1. Downey P, Cummins R, Moran M, et al: If it’s not CK5/6 positive, TTF-1 negative it’s not a squamous cell carcinoma of lung. Apmis 116:526–529, 2008.
2. Kargi A, Gurel D, Tuna B: The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 15:415–420, 2007.
3. Khayyata S, Yun S, Pasha T, et al: Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 37:178–183, 2009.
4. Rossi G, Papotti M, Barbareschi M, et al: Morphology and a limited number of immunohistochemical markers may efficiently subtype non–small-cell lung cancer. J Clin Oncol 27:e141–e142, 2009.
5. Bishop JA, Sharma R, IIIei PB. Napsin A and TTF-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesotheilioma. Human Pathol. 2010 Jan;41(1):20-5. Epub 2009 Sept 8.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.